65 related articles for article (PubMed ID: 15547728)
1. Antibody-mediated transduction of p53 selectively kills cancer cells.
Weisbart RH; Hansen JE; Chan G; Wakelin R; Chang SS; Heinze E; Miller CW; Koeffler PH; Yang F; Cole GM; Min YS; Nishimura RN
Int J Oncol; 2004 Dec; 25(6):1867-73. PubMed ID: 15547728
[TBL] [Abstract][Full Text] [Related]
2. Antibody-mediated p53 protein therapy prevents liver metastasis in vivo.
Hansen JE; Fischer LK; Chan G; Chang SS; Baldwin SW; Aragon RJ; Carter JJ; Lilly M; Nishimura RN; Weisbart RH; Reeves ME
Cancer Res; 2007 Feb; 67(4):1769-74. PubMed ID: 17308119
[TBL] [Abstract][Full Text] [Related]
3. Construction and expression of a bispecific single-chain antibody that penetrates mutant p53 colon cancer cells and binds p53.
Weisbart RH; Wakelin R; Chan G; Miller CW; Koeffler PH
Int J Oncol; 2004 Oct; 25(4):1113-8. PubMed ID: 15375563
[TBL] [Abstract][Full Text] [Related]
4. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments.
Caron de Fromentel C; Gruel N; Venot C; Debussche L; Conseiller E; Dureuil C; Teillaud JL; Tocque B; Bracco L
Oncogene; 1999 Jan; 18(2):551-7. PubMed ID: 9927212
[TBL] [Abstract][Full Text] [Related]
5. p51/p63, a novel p53 homologue, potentiates p53 activity and is a human cancer gene therapy candidate.
Kunisaki R; Ikawa S; Maeda T; Nakazaki Y; Kurita R; Harata M; Shutoh Y; Bai YS; Soda Y; Tanabe T; Dohi T; Kato R; Ikawa Y; Asano S; Tani K
J Gene Med; 2006 Sep; 8(9):1121-30. PubMed ID: 16832836
[TBL] [Abstract][Full Text] [Related]
6. p53: an overview of over two decades of study.
Cheah PL; Looi LM
Malays J Pathol; 2001 Jun; 23(1):9-16. PubMed ID: 16329542
[TBL] [Abstract][Full Text] [Related]
7. Generation of a selectively cytotoxic fusion protein against p53 mutated cancers.
Kousparou CA; Yiacoumi E; Deonarain MP; Epenetos AA
BMC Cancer; 2012 Aug; 12():338. PubMed ID: 22862878
[TBL] [Abstract][Full Text] [Related]
8. p53 protein transduction therapy: successful targeting and inhibition of the growth of the bladder cancer cells.
Inoue M; Tomizawa K; Matsushita M; Lu YF; Yokoyama T; Yanai H; Takashima A; Kumon H; Matsui H
Eur Urol; 2006 Jan; 49(1):161-8. PubMed ID: 16310931
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells.
Irie A; Matsumoto K; Anderegg B; Kuruma H; Kashani-Sabet M; Scanlon KJ; Uchida T; Baba S
Cancer Gene Ther; 2006 Mar; 13(3):298-305. PubMed ID: 16110311
[TBL] [Abstract][Full Text] [Related]
10. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
[TBL] [Abstract][Full Text] [Related]
11. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.
Idogawa M; Sasaki Y; Suzuki H; Mita H; Imai K; Shinomura Y; Tokino T
Clin Cancer Res; 2009 Jun; 15(11):3725-32. PubMed ID: 19458054
[TBL] [Abstract][Full Text] [Related]
12. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
Menendez JA; Lupu R
Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
[TBL] [Abstract][Full Text] [Related]
13. [Expression, purification and transduction of Tat-p53 fusion protein].
Ding J; Liu J; Huang YX; Li YH; Chen J; Zhao Y; Xue CF
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Sep; 21(5):587-90. PubMed ID: 16143063
[TBL] [Abstract][Full Text] [Related]
14. Mutations in p53 cDNA sequence introduced by retroviral vector.
Su S; Watanabe A; Yamamoto M; Nakajima E; Miyake K; Shimada T
Biochem Biophys Res Commun; 2006 Feb; 340(2):567-72. PubMed ID: 16380088
[TBL] [Abstract][Full Text] [Related]
15. Wild-type p53 in cancer cells: when a guardian turns into a blackguard.
Kim E; Giese A; Deppert W
Biochem Pharmacol; 2009 Jan; 77(1):11-20. PubMed ID: 18812169
[TBL] [Abstract][Full Text] [Related]
16. Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells.
Tokunaga N; Murakami T; Endo Y; Nishizaki M; Kagawa S; Tanaka N; Fujiwara T
Clin Cancer Res; 2005 Feb; 11(3):1312-8. PubMed ID: 15709203
[TBL] [Abstract][Full Text] [Related]
17. A recombinant cell-permeable p53 fusion protein is selectively stabilized under hypoxia and inhibits tumor cell growth.
Yu Z; Wu J; Wu S; Jia P; Tong Y; Wu X; Wang Y
Cancer Lett; 2009 Jun; 279(1):101-7. PubMed ID: 19232460
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway.
Zhang AL; Russell PJ; Knittel T; Milross C
Prostate; 2007 Nov; 67(15):1630-40. PubMed ID: 17823933
[TBL] [Abstract][Full Text] [Related]
19. Role of Stat3 in regulating p53 expression and function.
Niu G; Wright KL; Ma Y; Wright GM; Huang M; Irby R; Briggs J; Karras J; Cress WD; Pardoll D; Jove R; Chen J; Yu H
Mol Cell Biol; 2005 Sep; 25(17):7432-40. PubMed ID: 16107692
[TBL] [Abstract][Full Text] [Related]
20. Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells.
Choi SH; Jin SE; Lee MK; Lim SJ; Park JS; Kim BG; Ahn WS; Kim CK
Eur J Pharm Biopharm; 2008 Mar; 68(3):545-54. PubMed ID: 17881199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
